The deletion of ERO1α or inhibition with a small-molecule inhibitor B12-5 (IC50 = 7.9 μM) results in reduced infarct volume and improved neurological outcomes in ischemic stroke models, indicating that targeting ERO1α may offer potential benefits in stroke treatment. The gene discussed is ERO1A; the disease is stroke disorder.